Zenopharm, LLC was founded in 2012 to develop novel therapeutic products for the treatment of cancer. The company has a therapeutic portfolio that includes boron-based 4-hydroxytamoxifen and endoxifen prodrugs for treatment of breast cancer, several thiazole lead compounds that are potential anti-metastasis therapeutic regimens, and a novel anti-vasculature agent as inhibitor of tumor angiogenesis. The boron prodrugs were designed to combat de novo tamoxifen resistance and to reduce serious side effects associated with long-term tamoxifen therapy. The thiazole compounds were developed to inhibit cancer cell migration and invasion by specifically binding to fascin, an actin-bundling protein that plays a key role in tumor metastasis. The anti-vasculature agent inhibits tumor progression and metastasis by destroying existing vascular structure within the tumor and blocking new vascular formation. These drug candidates are currently under various stages of in vitro and in vivo preclinical tests.